Literature DB >> 15479811

A negative regulatory element (base pairs -204 to -177) of the EICP0 promoter of equine herpesvirus 1 abolishes the EICP0 protein's trans-activation of its own promoter.

Seong K Kim1, Randy A Albrecht, Dennis J O'Callaghan.   

Abstract

The early EICP0 protein is a powerful trans-activator that activates all classes of equine herpesvirus 1 (EHV-1) promoters but, unexpectedly, trans-activates its own promoter very weakly. Transient transfection assays that employed constructs harboring deletions within the EICP0 promoter indicated that EICP0 cis-acting sequences within bp -224 to -158 relative to the first ATG abolished the EICP0 protein's trans-activation of its own promoter. When inserted into the promoters of other EHV-1 genes, this sequence also downregulated activation of the immediate-early IE(-169/+73), early thymidine kinase TK(-215/+97), and late glycoprotein K gK(-83/+14) promoters, indicating that the cis-acting sequence (-224 to -158) downregulated expression of representative promoters of all classes of EHV-1 genes and contains a negative regulatory element (NRE). To define the cis-acting element(s), three synthetic oligonucleotides (Na [bp -224 to -195], Nb [bp -204 to -177], and Nc [bp -185 to -156]) were synthesized and cloned upstream of the EICP0(-157/-21) promoter. Of the three synthetic sequences, only the Nb oligonucleotide caused the downregulation of the EICP0 promoter. The NRE was identified as a 28-bp element to lie at -204 to -177 that encompassed the sequence of ([-204]AGATACAGATGTTCGATAAATTGGAACC[-177]). Gel shift assays performed with mouse L-M, rabbit RK-13, and human HeLa cell nuclear extracts and gamma-(32)P-labeled wild-type and mutant NREs demonstrated that a ubiquitous nuclear protein(s) (NRE-binding protein, NREBP) binds specifically to a sequence (bp -193 to -183) in the NRE. The NREBP is also present in the nucleus of EHV-1-infected cells; however, the amount of NREBP in EHV-1-infected L-M cells that bound to the Nb oligonucleotide was reduced compared to that in uninfected L-M cells. Transient transfection assays showed that deletions or mutations within the NREBP-binding site abolished the NRE activity of the EICP0 promoter. These results suggested that the NREBP may mediate the NRE activity of the EICP0 promoter and may function in the coordinate expression of EHV-1 genes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479811      PMCID: PMC523287          DOI: 10.1128/JVI.78.21.11696-11706.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

Review 1.  Role of ICP0 in the strategy of conquest of the host cell by herpes simplex virus 1.

Authors:  Ryan Hagglund; Bernard Roizman
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Does this have a familiar RING?

Authors:  A J Saurin; K L Borden; M N Boddy; P S Freemont
Journal:  Trends Biochem Sci       Date:  1996-06       Impact factor: 13.807

3.  Attenuation of DNA-dependent protein kinase activity and its catalytic subunit by the herpes simplex virus type 1 transactivator ICP0.

Authors:  S P Lees-Miller; M C Long; M A Kilvert; V Lam; S A Rice; C A Spencer
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Pseudorabies virus early protein 0 transactivates the viral gene promoters.

Authors:  S Watanabe; E Ono; Y Shimizu; H Kida
Journal:  J Gen Virol       Date:  1995-11       Impact factor: 3.891

5.  The RING finger domain of the varicella-zoster virus open reading frame 61 protein is required for its transregulatory functions.

Authors:  H Moriuchi; M Moriuchi; J I Cohen
Journal:  Virology       Date:  1994-11-15       Impact factor: 3.616

6.  Isolation and characterization of target sequences of the chicken CdxA homeobox gene.

Authors:  Y Margalit; S Yarus; E Shapira; Y Gruenbaum; A Fainsod
Journal:  Nucleic Acids Res       Date:  1993-10-25       Impact factor: 16.971

7.  Nuclear localization and transcriptional activation activities of truncated versions of the immediate-early gene product of equine herpesvirus 1.

Authors:  R H Smith; V R Holden; D J O'Callaghan
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

8.  Characterization of DNA binding properties of the immediate-early gene product of equine herpesvirus type 1.

Authors:  S K Kim; R H Smith; D J O'Callaghan
Journal:  Virology       Date:  1995-10-20       Impact factor: 3.616

9.  Characterization of the regulatory function of the ICP22 protein of equine herpesvirus type 1.

Authors:  V R Holden; Y Zhao; Y Thompson; G B Caughman; R H Smith; D J O'Callaghan
Journal:  Virology       Date:  1995-07-10       Impact factor: 3.513

10.  Regulatory function of the equine herpesvirus 1 ICP27 gene product.

Authors:  Y Zhao; V R Holden; R H Smith; D J O'Callaghan
Journal:  J Virol       Date:  1995-05       Impact factor: 6.549

View more
  4 in total

1.  The unique IR2 protein of equine herpesvirus 1 negatively regulates viral gene expression.

Authors:  Seong K Kim; Byung C Ahn; Randy A Albrecht; Dennis J O'Callaghan
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

2.  Expression of the full-length form of gp2 of equine herpesvirus 1 (EHV-1) completely restores respiratory virulence to the attenuated EHV-1 strain KyA in CBA mice.

Authors:  Patrick M Smith; Shannon M Kahan; Colin B Rorex; Jens von Einem; Nikolaus Osterrieder; Dennis J O'Callaghan
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  The equine herpesvirus-1 IR3 gene that lies antisense to the sole immediate-early (IE) gene is trans-activated by the IE protein, and is poorly expressed to a protein.

Authors:  Byung Chul Ahn; Jonathan E Breitenbach; Seong K Kim; Dennis J O'Callaghan
Journal:  Virology       Date:  2007-02-15       Impact factor: 3.616

4.  Initial characterization of 17 viruses harboring mutant forms of the immediate-early gene of equine herpesvirus 1.

Authors:  Kimberly A Buczynski; Seong K Kim; Dennis J O'Callaghan
Journal:  Virus Genes       Date:  2005-10       Impact factor: 2.332

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.